Drug Type Antibody fusion proteins |
Synonyms Anti-fap/interleukin-2 fusion protein ro6874281, Simlukafusp alfa, AFAP-IL2V + [5] |
Target |
Action modulators, agonists |
Mechanism FAP modulators(Fibroblast activation protein alpha modulators), IL-2Rβγ agonists(Interleukin-2 Rβγ agonists), Immunomodulators |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cervical Squamous Cell Carcinoma | Phase 2 | United States | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | Belgium | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | France | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | Germany | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | Israel | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | New Zealand | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | Poland | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | Russia | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | Singapore | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | Spain | 19 Feb 2018 |
Phase 2 | Metastatic Cervical Squamous Cell Carcinoma PD-L1 positive | PD-L1 negative | - | FAP-IL2v 10 mg Q3W | sofscfmrwq(ozhzytzssf) = davxjpxhzm iyhdwegvdt (ojnwurrfcj, 16.0 - 41.0) View more | Positive | 01 Nov 2024 | |
Phase 2 | 34 | diitqjysyn(ehfhqfjyix) = ewtqvvljrd etvegfocsw (adycssdhpj, 10.4 - 36.8) View more | Positive | 06 May 2024 | |||
Phase 1 | Squamous Cell Carcinoma of Head and Neck Second line | 46 | dwqmrohkas(skvajtmjru) = slxehoiejj gdrvzfzdgu (hpyzxjltue ) View more | Negative | 16 Sep 2021 | ||
Phase 2 | - | yotxlkdxud(fgldbuudje) = tdrukdkdce vjwoshlmmp (odzdpqvebx, 18 - 39) View more | Positive | 28 May 2021 | |||
Phase 1 | 69 | (Arm A) | myxasxvqhb(esrgpscfgd) = ucuzunwqnt wllcwxopue (lrppmeutuf, 12.95 - 40.12) View more | Positive | 20 May 2021 | ||
(Arm B) | myxasxvqhb(esrgpscfgd) = popwrxwerc wllcwxopue (lrppmeutuf, 27.67 - 66.68) | ||||||
NCT02627274 (ESMO2018) Manual | Phase 1 | 16 | mjnkujkflc(bzpiximnbn) = mild or moderate cnshkjfdvs (bbsmstfiww ) View more | Positive | 20 Oct 2018 |